Chat with us, powered by LiveChat

Online

Nitrosoureas and beyond: What to do when the CPCA doesn’t apply – Korea

Co-hosted with BITEK CHEMS on April 16th, this bilingual event was hosted in Korean, and include translated presentations from expert Lhasa and Consult Lhasa scientists. Experts David Ponting (Principal Scientist, Lhasa Limited) and Natan Segretti (CSO, Consult Lhasa) presented an explorative webinar on the recently updated EMA guidelines for nitrosoureas risk assessment.   Natan provided […]

Nitrosoureas and beyond: What to do when the CPCA doesn’t apply – Korea Read More »

Nitrosoureas and beyond: What to do when the CPCA doesn’t apply – Japan

This bilingual event was hosted in Japanese, and included translated presentations from expert Lhasa and Consult Lhasa scientists. Experts David Ponting (Principal Scientist, Lhasa Limited) and Natan Segretti (CSO, Consult Lhasa) presented an explorative webinar on the recently updated EMA guidelines for nitrosoureas risk assessment.   Natan provided a comprehensive overview of this critical regulatory

Nitrosoureas and beyond: What to do when the CPCA doesn’t apply – Japan Read More »

Nitrosoureas and beyond: What to do when the CPCA doesn’t apply

Experts David Ponting (Principal Scientist, Lhasa Limited) and Natan Segretti (CSO, Consult Lhasa), delivered an explorative webinar on the recently updated EMA guidelines for nitrosoureas risk assessment.   Natan provided a comprehensive overview of this critical regulatory update, explaining why nitrosoureas are classified within the cohort of concern and the reasoning behind these new regulatory

Nitrosoureas and beyond: What to do when the CPCA doesn’t apply Read More »

4th Annual Genotoxic Impurities Summit: Nitrosamines & Beyond 2024

We were delighted to be on the programme at the 4th Annual Genotoxic Impurities Summit. Lhasa Principal Scientist Michael Burns presented ‘Reactivities of N-nitrosamines against Common Reagents and Reaction Conditions’. Impurities may have a negative effect on the efficacy, safety, and quality of pharmaceutical components and products. The successful development and manufacturing of novel medications now

4th Annual Genotoxic Impurities Summit: Nitrosamines & Beyond 2024 Read More »

Ensuring API safety: Strategies for impurity and degradant management under ICH M7

Managing impurities in Active Pharmaceutical Ingredients (APIs) while meeting ICH M7 can be challenging. The need to quickly identify potential impurities, assess their toxicological risk and ensure compliance with mutagenicity and carcinogenicity guidelines demands a streamlined, reliable process. Held in Spanish, this webinar showcased how in silico tools Zeneth, Derek Nexus, and Sarah Nexus can

Ensuring API safety: Strategies for impurity and degradant management under ICH M7 Read More »

How to develop impurity control strategies without analytical testing

10 am (EST) / 3 pm (GMT) / 4pm (CET) This webinar detailed how to develop control strategies in line with ICH M7 guidelines without expensive and time-consuming analytical testing. We showed how you can assess carryover risk for potentially mutagenic impurities (including nitrosamines) in your drug development workflow. We were delighted to have Senior

How to develop impurity control strategies without analytical testing Read More »

Analytical challenges and the effective management of nitrosamines: The evolving landscape of NDSRI analysis

We were delighted to take part in an online seminar and panel discussion with ThermoFisher Scientific on 29th October. Nitrosamine Drug Substance related impurities (NDSRIs) remain a topic of significant concern to the pharmaceutical industry with multiple batch recalls in 2022+ across different drug classes including beta blockers and ACE inhibitors to name but a

Analytical challenges and the effective management of nitrosamines: The evolving landscape of NDSRI analysis Read More »

Classification of potentially mutagenic impurities under the ICH M7 guideline

Watch our Lhasa webinar to deepen your understanding of the ICH M7 guidelines and their application in classifying mutagenic impurities.   Learn from regulatory and industry leaders through expert presentations and real-world case studies. The webinar agenda includes: Introduction to ICH M7 guidelines Dr Roland Froetschl, from the Federal Institute for Drugs and Medical Devices,

Classification of potentially mutagenic impurities under the ICH M7 guideline Read More »

Integrating ReproTracker into DART AOP Frameworks for mechanism-based teratogenicity assessment

Lhasa Limited Principal Scientist, Alun Myden, presented in webinar hosted by Toxys on the use of DART AOP frameworks for mechanism-based teratogenicity assessment.   Testing for developmental toxicity according to the current guidelines requires large numbers of animals. In addition to the ethical considerations and high costs of these traditional animal models, the outputs provide

Integrating ReproTracker into DART AOP Frameworks for mechanism-based teratogenicity assessment Read More »